ASSESSMENT OF THE SAFETY AND EFFICACY OF PARACETAMOL IN THE MANAGEMENT OF HEMODYNAMICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PRETERM NEWBORNS

Authors

  • Dr Shailesh Patel
  • Dr. Sreya Todi
  • Dr. Mohit Kulmi

Keywords:

hemodynamically significant patent ductus arteriosus, , hdPDA, paracetamol, , preterm infants, NICU

Abstract

Background: In preterm babies, hemodynamically significant patent ductus arteriosus (hsPDA) causes significant mortality
and morbidity affecting 20%very of birth weight infants where medical management is the main modality. Conventionally
used cyclooxygenase inhibitors have many serious adverse effects warranting alternative drugs such as paracetamol to be
used in NICU in preterm neonates with hsPDA.
Aim: The present study aimed to assess the safety and efficacy of paracetamol in preterm neonates having
hemodynamically significant patent ductus arteriosus (hsPDA).
Methods: The present study assessed 28 preterm neonates who were diagnosed with hemodynamically significant patent
ductus arteriosus on echocardiographic and clinical assessment in NICU (neonatal intensive care unit) on days 3-14 of life
for 13 months. Birth weight of 1000 grams and 1650 grams and gestational age of 28-33 weeks were assessed in the study.
Paracetamol in the dose of 15mg/kg/dose every 6 hours was given to all the neonates for 3 days and neonates were
echocardiographically reevaluated after 3 days of the treatment

Downloads

Published

11-12-2024